MyoVector

Head: Sofia Benkhelifa-Ziyyat

MyoVector produces gene therapy vectors from adeno-associated viruses (AAV) with a high level of quality and complete traceability of the final product. AAV vectors are used to express therapeutic transgenes, reporter genes (GFP, luciferase, LacZ, mSEAP) or other constructs (CrispCas9, shRNA, U7snRNA).

By combining our expertise with the expertise of Genethon, a scalable production method for preclinical and clinical applications is currently being developed in MyoVector with the support of the DIM Thérapie Génique.

By 2023, MyoVector supplied vectors to 8 teams at the Center of Research and:

  • signed an MTA with Dirk Grimm (Heidelberg University Hospital) for the production of AAVmyo for the Research Centre teams, followed by optimisation of this production,
  • provided the research teams with a bank of AAV vectors (serotypes 1-10), single- and double-stranded, carrying reporter genes,
  • produced AAV vectors expressing transgenes targeting different sub-cellular compartments, then tested in human muscle cells (in collaboration with MyoMolBio, MyoLine and MyoImage).